Health Affairs July 12, 2024
Policymakers have long reckoned with the persistent challenge of high insulin prices. In recent years, there have been efforts to increase competition through antitrust action, creating a “public option” through state-run manufacturing, and controlling costs through caps on out-of-pocket payments and mandatory rebates for price increases outpacing inflation. The high concentration of insulin markets – three companies control 100% of insulin production in the United States and 90% worldwide – is considered to be a key factor in the intractably high prices of insulin. Alongside price, the downstream effects of limited competition on supply stability are increasingly coming into focus. The U.S. House of Representatives Energy and Commerce Committee and the Senate Health, Education, Labor, and Pensions (HELP) and Finance...
Today's Sponsors
Today's Sponsor